Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | Director | June 17, 2026 | June 22, 2026 |
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | EVP & CFO | March 05, 2019 | March 08, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytomX Therapeutics, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.96 · Expires 2036-06-16 | Direct | 59,000 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 59,000 · Balance 59,000 F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
Jazz Pharmaceuticals plc
Report date March 05, 2019 · Filed March 08, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 36,200 |
Ending reported balance
After 2019-03-06 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-03-05 · Tax withholding · Disposed 1,267 · Balance 38,700 F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Row 2 · 2019-03-05 · Tax withholding · Disposed 1,348 · Balance 37,352 F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Row 3 · 2019-03-06 · Sale · Disposed 1,152 · Balance 36,200 F2: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.
F2: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PRA Health Sciences, Inc.
Report date July 01, 2021 · Filed July 01, 2021
Section 16 reporting ended · disclosed 2021-07-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-07-01 transaction · row 1
1 source rowRow 1 · 2021-07-01 · Disposition to issuer · Disposed 7,127 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (as it may be amended from time to time) (the "Merger Agreement"), dated as of February 24, 2021, by and among the Issuer, ICON plc ("ICON"), ICON US Holdings Inc. ("US HoldCo") and Indigo Merger Sub, Inc., each share of the Issuer's common stock was converted into the right to receive from ICON, 0.4125 of one ordinary share of ICON, and, from US HoldCo, $80.00 in cash, without any interest thereon (collectively, the "Merger Consideration"). F2: Pursuant to the Merger Agreement, each award of restricted stock of the Issuer that is outstanding immediately prior to the effective time of the merger was converted into the right to receive the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (as it may be amended from time to time) (the "Merger Agreement"), dated as of February 24, 2021, by and among the Issuer, ICON plc ("ICON"), ICON US Holdings Inc. ("US HoldCo") and Indigo Merger Sub, Inc., each share of the Issuer's common stock was converted into the right to receive from ICON, 0.4125 of one ordinary share of ICON, and, from US HoldCo, $80.00 in cash, without any interest thereon (collectively, the "Merger Consideration").
F2: Pursuant to the Merger Agreement, each award of restricted stock of the Issuer that is outstanding immediately prior to the effective time of the merger was converted into the right to receive the Merger Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 22, 2026 20:52 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 59,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001610717-26-000279 · form4.xml · derivative · entry 1 Young Matthew P. · CIK 0001601583 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,000 Underlying: Common Stock · 59,000 shares Expires 2036-06-16 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:18 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 38,000 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001610717-25-000214 · form4.xml · derivative · entry 1 Young Matthew P. · CIK 0001601583 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| May 15, 2024 Filed May 17, 2024 21:36 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 38,000 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001610717-24-000248 · form4.xml · derivative · entry 1 Young Matthew P. · CIK 0001601583 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2034-05-14 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:51 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001610717-23-000181 · form4.xml · derivative · entry 1 Young Matthew P. · CIK 0001601583 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-13 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2024 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:07 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001567619-22-013075 · doc1.xml · derivative · entry 1 Young Matthew P. · CIK 0001601583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2023 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| July 01, 2021 Filed Jul 1, 2021 21:43 UTC | PRA Health Sciences, Inc. PRAH · Entity 15912 | Disposition to issuerCommon Stock | 7,127 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-088359 · tm2121280-6_4seq1.xml · nonDerivative · entry 1 Young Matthew P. · CIK 0001601583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger (as it may be amended from time to time) (the "Merger Agreement"), dated as of February 24, 2021, by and among the Issuer, ICON plc ("ICON"), ICON US Holdings Inc. ("US HoldCo") and Indigo Merger Sub, Inc., each share of the Issuer's common stock was converted into the right to receive from ICON, 0.4125 of one ordinary share of ICON, and, from US HoldCo, $80.00 in cash, without any interest thereon (collectively, the "Merger Consideration"). F2 · price: Pursuant to the Merger Agreement, each award of restricted stock of the Issuer that is outstanding immediately prior to the effective time of the merger was converted into the right to receive the Merger Consideration. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 22:47 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $7.13 | $0.00 |
DisclosureSEC source: 0001567619-21-012371 · doc1.xml · derivative · entry 1 Young Matthew P. · CIK 0001601583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2022 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:05 UTC | PRA Health Sciences, Inc. PRAH · Entity 15912 | GrantCommon Stock | 250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-076362 · tm2118302-9_4seq1.xml · nonDerivative · entry 1 Young Matthew P. · CIK 0001601583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,127 F1 · kind: Represents a grant of restricted stock granted under the PRA Health Sciences, Inc. 2020 Stock Incentive Plan that will vest on June 1, 2022, subject to continued service on such date. Further, the grant shall vest in full upon a change in control as defined under the applicable award agreement. Read SEC document |
| June 17, 2020 Filed Jun 17, 2020 21:12 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $8.35 | $0.00 |
DisclosureSEC source: 0001567619-20-012304 · doc1.xml · derivative · entry 1 Young Matthew P. · CIK 0001601583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| May 18, 2020 Filed May 20, 2020 20:57 UTC | PRA Health Sciences, Inc. PRAH · Entity 15912 | GrantCommon Stock | 1,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-064309 · a4.xml · nonDerivative · entry 1 Young Matthew P. · CIK 0001601583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,877 F1 · kind: Represents a grant of restricted stock that will vest on the first anniversary of the grant date, subject to continued service on such date. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 18:05 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $11.31 | $0.00 |
DisclosureSEC source: 0001567619-19-013826 · doc1.xml · derivative · entry 1 Young Matthew P. · CIK 0001601583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2020 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 21:04 UTC | PRA Health Sciences, Inc. PRAH · Entity 15912 | GrantCommon Stock | 1,436 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-034065 · a4.xml · nonDerivative · entry 1 Young Matthew P. · CIK 0001601583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,553 F1 · kind: Represents a grant of restricted stock that will vest on the first anniversary of the grant date, subject to continued service on such date. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 00:13 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,152 | $135.41 | $155,992.32 |
DisclosureSEC source: 0001765581-19-000041 · edgardoc.xml · nonDerivative · entry 3 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,200 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 05, 2019 Filed Mar 8, 2019 00:13 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,348 | $135.82 | $183,085.36 |
DisclosureSEC source: 0001765581-19-000041 · edgardoc.xml · nonDerivative · entry 2 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,352 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 05, 2019 Filed Mar 8, 2019 00:13 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,267 | $135.82 | $172,083.94 |
DisclosureSEC source: 0001765581-19-000041 · edgardoc.xml · nonDerivative · entry 1 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,700 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:45 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 29,286 | $0.00 Strike: $140.03 | $0.00 |
DisclosureSEC source: 0001765581-19-000029 · edgardoc.xml · derivative · entry 3 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,286 Underlying: Ordinary Shares · 29,286 shares Expires 2029-02-27 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 28, 2019, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:45 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantIncentive Stock Option (right to buy) · Derivative | 714 | $0.00 Strike: $140.03 | $0.00 |
DisclosureSEC source: 0001765581-19-000029 · edgardoc.xml · derivative · entry 2 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 714 Underlying: Ordinary Shares · 714 shares Expires 2029-02-27 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 28, 2019, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:45 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-19-000029 · edgardoc.xml · nonDerivative · entry 1 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,967 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| February 27, 2019 Filed Feb 28, 2019 01:38 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 884 | $137.91 | $121,912.44 |
DisclosureSEC source: 0001765581-19-000012 · edgardoc.xml · nonDerivative · entry 4 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,967 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 01:38 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,034 | $127.76 | $132,103.84 |
DisclosureSEC source: 0001765581-19-000012 · edgardoc.xml · nonDerivative · entry 3 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,851 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 01:38 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,032 | $125.93 | $129,959.76 |
DisclosureSEC source: 0001765581-19-000012 · edgardoc.xml · nonDerivative · entry 2 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,885 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 25, 2019 Filed Feb 28, 2019 01:38 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,218 | $126.25 | $153,772.50 |
DisclosureSEC source: 0001765581-19-000012 · edgardoc.xml · nonDerivative · entry 1 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,917 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. F2 · balance_after: Includes 67 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2018. Read SEC document |
| November 23, 2018 Filed Nov 27, 2018 21:54 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 700 | $150.00 | $105,000.00 |
DisclosureSEC source: 0001232524-18-000198 · edgardoc.xml · nonDerivative · entry 1 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,068 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 20:29 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 700 | $158.08 | $110,657.96 |
DisclosureSEC source: 0001232524-18-000180 · edgardoc.xml · nonDerivative · entry 1 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,768 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $158.0762 to $158.0916. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 21:05 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 700 | $162.70 | $113,890.00 |
DisclosureSEC source: 0001232524-18-000171 · edgardoc.xml · nonDerivative · entry 1 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,468 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 22:57 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 700 | $176.05 | $123,235.00 |
DisclosureSEC source: 0001232524-18-000165 · edgardoc.xml · nonDerivative · entry 1 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,168 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 21:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 700 | $176.06 | $123,242.00 |
DisclosureSEC source: 0001232524-18-000121 · edgardoc.xml · nonDerivative · entry 1 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,868 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 20:06 UTC | PRA Health Sciences, Inc. PRAH · Entity 15912 | GrantCommon Stock | 1,307 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-042050 · a4.xml · nonDerivative · entry 1 Young Matthew P. · CIK 0001601583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,117 F1 · kind: Represents a grant of restricted stock which will vest fifty percent on each of the first two anniversaries of the grant date, subject to continued service on such dates. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 20:26 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 700 | $176.99 | $123,893.00 |
DisclosureSEC source: 0001232524-18-000115 · edgardoc.xml · nonDerivative · entry 1 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,568 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 21:49 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $25.25 | $0.00 |
DisclosureSEC source: 0000899243-18-016820 · doc4.xml · derivative · entry 1 Young Matthew P. · CIK 0001601583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2028-06-12 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2019 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 22:52 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $58.72 | $0.00 |
DisclosureSEC source: 0001232524-18-000109 · edgardoc.xml · derivative · entry 3 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,192 Underlying: Ordinary Shares · 5,000 shares Expires 2023-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: This non-qualified stock option is part of an option award granted on May 3, 2013. The ordinary shares subject to the option award vested over 4 years from the vesting commencement date of April 22, 2013, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of April 22, 2017. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 22:52 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 5,000 | $170.04 | $850,212.00 |
DisclosureSEC source: 0001232524-18-000109 · edgardoc.xml · nonDerivative · entry 2 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,268 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $170.0000 to $170.3100. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 22:52 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 5,000 | $58.72 | $293,600.00 |
DisclosureSEC source: 0001232524-18-000109 · edgardoc.xml · nonDerivative · entry 1 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,268 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 65 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2018. Read SEC document |
| May 15, 2018 Filed May 16, 2018 20:54 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,420 | $164.64 | $233,788.80 |
DisclosureSEC source: 0001232524-18-000105 · edgardoc.xml · nonDerivative · entry 2 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,203 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| May 14, 2018 Filed May 16, 2018 20:54 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 842 | $166.00 | $139,772.00 |
DisclosureSEC source: 0001232524-18-000105 · edgardoc.xml · nonDerivative · entry 1 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,623 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 21:09 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 700 | $156.01 | $109,207.00 |
DisclosureSEC source: 0001232524-18-000080 · edgardoc.xml · nonDerivative · entry 1 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,465 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 15, 2018 Filed Mar 19, 2018 20:44 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 700 | $151.22 | $105,854.00 |
DisclosureSEC source: 0001232524-18-000072 · edgardoc.xml · nonDerivative · entry 1 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,165 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 21:10 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 352 | $143.04 | $50,350.29 |
DisclosureSEC source: 0001232524-18-000059 · edgardoc.xml · nonDerivative · entry 3 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,865 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $142.6400 to $143.4400. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 21:10 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 800 | $142.06 | $113,648.00 |
DisclosureSEC source: 0001232524-18-000059 · edgardoc.xml · nonDerivative · entry 2 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,217 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $141.4500 to $142.4200. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 21:10 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,348 | $143.39 | $193,289.72 |
DisclosureSEC source: 0001232524-18-000059 · edgardoc.xml · nonDerivative · entry 1 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,017 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:39 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 22,790 | $0.00 Strike: $140.67 | $0.00 |
DisclosureSEC source: 0001232524-18-000050 · edgardoc.xml · derivative · entry 3 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,790 Underlying: Ordinary Shares · 22,790 shares Expires 2028-02-29 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 1, 2018, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:39 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantIncentive Stock Option (right to buy) · Derivative | 710 | $0.00 Strike: $140.67 | $0.00 |
DisclosureSEC source: 0001232524-18-000050 · edgardoc.xml · derivative · entry 2 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 710 Underlying: Ordinary Shares · 710 shares Expires 2028-02-29 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 1, 2018, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:39 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 9,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001232524-18-000050 · edgardoc.xml · nonDerivative · entry 1 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,365 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2018, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| February 28, 2018 Filed Feb 28, 2018 22:57 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 700 | $150.00 | $105,000.00 |
DisclosureSEC source: 0001232524-18-000032 · edgardoc.xml · nonDerivative · entry 9 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,965 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 28, 2018 Filed Feb 28, 2018 22:57 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 200 | $149.02 | $29,803.00 |
DisclosureSEC source: 0001232524-18-000032 · edgardoc.xml · nonDerivative · entry 8 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,665 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F8 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $148.6200 to $149.4100. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| February 28, 2018 Filed Feb 28, 2018 22:57 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 119 | $147.56 | $17,559.18 |
DisclosureSEC source: 0001232524-18-000032 · edgardoc.xml · nonDerivative · entry 7 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,865 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F7 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $147.2200 to $147.6200. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| February 28, 2018 Filed Feb 28, 2018 22:57 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 200 | $145.25 | $29,049.00 |
DisclosureSEC source: 0001232524-18-000032 · edgardoc.xml · nonDerivative · entry 6 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,984 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $145.0500 to $145.4400. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 22:57 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 606 | $143.80 | $87,142.80 |
DisclosureSEC source: 0001232524-18-000032 · edgardoc.xml · nonDerivative · entry 5 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,184 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 22:57 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 300 | $147.30 | $44,189.01 |
DisclosureSEC source: 0001232524-18-000032 · edgardoc.xml · nonDerivative · entry 4 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,790 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $147.0600 to $147.4400. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 22:57 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 600 | $145.83 | $87,499.98 |
DisclosureSEC source: 0001232524-18-000032 · edgardoc.xml · nonDerivative · entry 3 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,090 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $145.4300 to $146.2700. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.